肌少性肥胖与心血管疾病研究进展

doi:10.3969/j.issn.1003-9198.2025.07.017

摘要/Abstract

摘要： 中国心血管疾病在死亡病因中位居榜首。心血管疾病的危险因素有很多,现如今普遍认为的重要危险因素是高龄、吸烟、肥胖、高血压、高血脂、糖尿病、饮食结构不合理、缺乏体育锻炼等。随着中国人口老龄化程度不断加深,65岁以上人群中肥胖合并肌少症的发生率呈递增趋势,其与心血管疾病之间的关系也一直备受关注。本文对肌少性肥胖与心血管疾病研究进展进行了综述。

关键词: 心血管疾病, 肌少性肥胖, 老年人, 研究进展

Abstract: Cardiovascular diseases rank first among the causes of mortality in China. There are many risk factors for cardiovascular disease, and currently, the most widely recognized causative factors include advanced age, smoking, obesity, hypertension, hyperlipidemia, diabetes, poor dietary habits, and lack of physical exercise. With the aging of China’s population, the incidence of obesity combined with sarcopenia in people over 65 years old is increasing. The relationship between sarcopenic obesity and cardiovascular disease has been attracting much attention. This paper reviews the research progress on sarcopenic obesity and cardiovascular disease.

Key words: cardiovascular disease, sarcopenic obesity, aged, progress

中图分类号:

R541
R543

高莹, 梁伟. 肌少性肥胖与心血管疾病研究进展[J]. 实用老年医学, 2025, 39(7): 732-736.

GAO Ying, LIANG Wei. Advances in the study of sarcopenic obesity and cardiovascular disease[J]. Practical Geriatrics, 2025, 39(7): 732-736.

参考文献

[1] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307. e2.
[2] LIANG C K, PENG L N, LIN M H, et al. Long-term mortality risk in older adults with sarcopenia: an 11-year prospective cohort study comparing AWGS 2014 and AWGS 2019 guidelines for enhanced clinical utility and accurate risk prediction[J]. J Nutr Health Aging, 2023, 27(7): 507-513.
[3] 曲伸, 陆灏, 宋勇峰. 基于临床的肥胖症多学科诊疗共识(2021年版)[J]. 中华肥胖与代谢病电子杂志, 2021, 7(4): 211-226.
[4] DONINI L M, BUSETTO L, BISCHOFF S C, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement[J]. Obes Facts, 2022, 15(3): 321-335.
[5] 龙囡囡, 吴玉泉. 肌少症的认识及其研究进展[J]. 中华保健医学杂志, 2018, 20(5): 447-450.
[6] 任姗姗, 杨子艳, 汪明芳, 等. 三种诊断标准应用于老年肌少症性肥胖的比较[J]. 中国临床医生杂志, 2021, 49(6): 672-674.
[7] QIN Z, ZHAO J, LI J, et al. Low lean mass is associated with lower urinary tract symptoms in US men from the 2005-2006 national health and nutrition examination survey dataset[J]. Aging, 2021, 13(17): 21421-21434.
[8] PRADO C M, BATSIS J A, DONINI L M, et al. Sarcopenic obesity in older adults: a clinical overview[J]. Nat Rev Endocrinol, 2024, 20(5): 261-277.
[9] PELLEGRINO A, TIIDUS P M, VANDENBOOM R. Mechanisms of estrogen influence on skeletal muscle: mass, regeneration, and mitochondrial function[J]. Sports Med, 2022, 52(12): 2853-2869.
[10] SATO M, TAMURA Y, MURAO Y, et al. Coexistence of high visceral fat area and sarcopenia is associated with atherosclerotic markers in old-old patients with diabetes: a cross-sectional study[J]. J Diabetes Investig, 2024, 15(10): 1510-1518.
[11] BEKKERING S, SANER C, RIKSEN N P, et al. Trained immunity: linking obesity and cardiovascular disease across the life-course?[J]. Trends Endocrinol Metab, 2020, 31(5): 378-389.
[12] PARK J E, HAN J S. HM-chromanone, a major homoisoflavonoid in Portulaca oleracea L. , improves palmitate-induced insulin resistance by regulating phosphorylation of IRS-1 residues in L6 skeletal muscle cells[J]. Nutrients, 2022, 14(18): 3815.
[13] LIU X, WANG K, WANG L, et al. Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity[J]. Hepatology, 2023, 78(2): 562-577.
[14] HONG S H, CHOI K M. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences[J]. Int J Mol Sci, 2020, 21(2): 494.
[15] SKALS R, KROGAGER M L, APPEL E V R, et al. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography[J]. PLoS One, 2021, 16(6): e0252855.
[16] WU Q, BURLEY G, LI L C, et al. The role of dietary salt in metabolism and energy balance: insights beyond cardiovascular disease[J]. Diabetes Obes Metab, 2023, 25(5): 1147-1161.
[17] OOST L J, TACK C J, DE BAAIJ J H F. Hypomagnesemia and cardiovascular risk in type 2 diabetes[J]. Endocr Rev, 2023, 44(3): 357-378.
[18] POETSCH M S, STRANO A, GUAN K. Role of leptin in cardiovascular diseases[J]. Front Endocrinol:Lausanne, 2020, 11: 354.
[19] MITSIOU G, KARATZANOS E, SMILIOS I, et al. Exercise promotes endothelial progenitor cell mobilization in patients with chronic heart failure[J]. Eur J Prev Cardiol, 2022, 28(18): e24-e27.
[20] NIEMANN B, LI L, SIEGLER D, et al. CTRP9 mediates protective effects in cardiomyocytes via AMPK- and adiponectin receptor-mediated induction of anti-oxidant response[J]. Cells, 2020, 9(5): 1229.
[21] DE OLIVEIRA DOS SANTOS A R, DE OLIVEIRA ZANUSO B, MIOLA V F B, et al. Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions[J]. Int J Mol Sci, 2021, 22(5): 2639.
[22] OJIMA C, NOGUCHI Y, MIYAMOTO T, et al. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia[J]. Cancer Sci, 2020, 111(8): 2954-2964.
[23] CARDOSO A C, LAM N T, SAVLA J J, et al. Mitochondrial substrate utilization regulates cardiomyocyte cell cycle progression[J]. Nat Metab, 2020, 2(2): 167-178.
[24] SCHWINGER R H G. Pathophysiology of heart failure[J]. Cardiovasc Diagn Ther, 2021, 11(1): 263-276.
[25] FATMI M K, REN D, FEDOROVA J, et al. Cardiomyocyte Pdk4 response is associated with metabolic maladaptation in aging[J]. Aging Cell, 2023, 22(4): e13800.
[26] LI J, QI F, SU H, et al. GRP75-faciliated mitochondria-associated ER membrane (MAM) integrity controls cisplatin-resistance in ovarian cancer patients[J]. Int J Biol Sci, 2022, 18(7): 2914-2931.
[27] GHARAHDAGHI N, PHILLIPS B E, SZEWCZYK N J, et al. Links between testosterone, oestrogen, and the growth hormone/insulin-like growth factor axis and resistance exercise muscle adaptations[J]. Front Physiol, 2021, 11: 621226.
[28] GOMEZ-DELGADO F, KATSIKI N, LOPEZ-MIRANDA J, et al. Dietary habits, lipoprotein metabolism and cardiovascular disease: from individual foods to dietary patterns[J]. Crit Rev Food Sci Nutr, 2021, 61(10): 1651-1669.
[29] CRUZ-TOPETE D, DOMINIC P, STOKES K Y. Uncovering sex-specific mechanisms of action of testosterone and redox balance[J]. Redox Biol, 2020, 31: 101490.
[30] DORLING J L, APOLZAN J W, JOHANNSEN N M, et al. Exercise-induced changes in central adiposity during an RCT: effect of exercise dose and associations with compensation[J]. J Clin Endocrinol Metab, 2024, 109(3): e997-e1005.
[31] MILLER M G, PORTER STARR K N, RINCKER J, et al. Rationale and design for a higher (dairy) protein weight loss intervention that promotes muscle quality and bone health in older adults with obesity: a randomized, controlled pilot study[J]. J Nutr Gerontol Geriatr, 2021, 40(2/3): 150-170.
[32] CHI M, NIE Y, SU Y, et al. Effects of weight loss in heart failure patients with overweight and obesity: a systematic review and meta-analysis[J]. Eur J Prev Cardiol, 2023, 30(17): 1906-1921.
[33] ISLAMI F, BAEKER BISPO J, LEE H, et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2023[J]. CA Cancer J Clin, 2024, 74(2): 136-166.
[34] HEJAZI K, MOHAMMAD RAHIMI G R, ROSENKRANZ S K. Effects of exercise training on inflammatory and cardiometabolic risk biomarkers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials[J]. Biol Res Nurs, 2023, 25(2): 250-266.
[35] VAN VOSSEL K, HARDEEL J, VAN DE CASTEELE F, et al. Can muscle typology explain the inter-individual variability in resistance training adaptations?[J]. J Physiol, 2023, 601(12): 2307-2327.